22 collaboration projects will receive a total of 1,25 Million Euros from PERMIDES for innovation projects between small and medium sized enterprises (SMEs) from biopharma, bioinformatics and the IT sector.
One of the lucky companies to receive innovation funding is Oslo Cancer Cluster member Myhere. For MyHere, it was especially important that the PERMIDES initiative is focused on the intersection between BioPharma and IT.
– Working with partners that are specialized in our field makes it easier to communicate the mission we are on, the concrete problems we are trying to solve and to qualify if we are a good match for each other or not. Furthermore, as we learned about the people and companies involved with PERMIDES, we discovered that we could learn a lot from the experiences of other SMEs in the program, says Jon-Bendik Thue, CEO at MyHere.
An innovative health app
MyHere’s mission is mainly carried out through the use of their app. This app, which pinpoints levels of Prostate Specific Antigen (PSA) in the bloodstream, enables a clearer outlook on potential prostate cancer and when to promptly, and timely, seek help. Thus, this app creates a balanced overview of prostate cancer that can save the patient and doctor from underdoing and overdoing the process. Essentially, the app is designed to save lives.
In this video, from MyHere’s webpage, the company explains the concept:
Essential health data
The funding will enable MyHere to start with a project that manages content from owners of health data. Health data is a tremendous resource, but unfortunately also tremendously underutilized. One important factor is the issue with getting consent from the owner of health data for research purposes. Typically, the owner is the individual the information was generated from, often in the role as a patient.
– As a provider of medical services directly to consumers, while at the same time organizing data across patient journeys, we are in a unique position to help solve the issue with consent for use of data. The funding from PERMIDES will allow us to build a dynamic data owner content management system, that will be integrated into our medical service platform. We are very excited about this project and we look forward to implementing it with our partner FramX, says Thue.
– Without this funding, we would have had to postpone the initiative without knowing when we would be able to realize it. Now we are thrilled that we will be able to hit the ground running right after the short Norwegian summer, he adds.
More winners in this round
Another Oslo Cancer Cluster member that got funding in this PERMIDES call is Arctic Pharma, a small start-up company committed to developing innovative anti-cancer drugs by exploiting the peculiar metabolic features of cancer cells.
These two Oslo Cancer Cluster members were among six Norwegian companies involved in four successful applications for Innovation Voucher funding. All of them will be able to initiate their joint projects in August and expect to see results early next year.